

Panama

Population 2016

4 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.22 (0.2–0.25)	5.5 (4.9–6.1)
Mortality (HIV+TB only)	0.052 (0.036–0.07)	1.3 (0.89–1.7)
Incidence (includes HIV+TB)	2.2 (1.7–2.8)	55 (42–70)
Incidence (HIV+TB only)	0.25 (0.16–0.36)	6.2 (4–8.9)
Incidence (MDR/RR-TB)**	0.096 (0.057–0.14)	2.4 (1.4–3.4)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.12 (0.088–0.15)	0.65 (0.48–0.81)	0.76 (0.57–0.95)
Males	0.13 (0.099–0.16)	1.3 (1–1.7)	1.5 (1.1–1.8)
Total	0.25 (0.19–0.31)	2 (1.5–2.5)	2.2 (1.7–2.8)

TB case notifications, 2016

Total cases notified	1 858
Total new and relapse	1 787
- % tested with rapid diagnostics at time of diagnosis	24%
- % with known HIV status	96%
- % pulmonary	82%
- % bacteriologically confirmed among pulmonary	59%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.12 (0.09–0.16)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	190	11%
- on antiretroviral therapy	190	100%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			68 (41–94)
Estimated % of TB cases with MDR/RR-TB	2.9% (1.4–4.5)	17% (8.9–29)	
% notified tested for rifampicin resistance	21%	31%	589
MDR/RR-TB cases tested for resistance to second-line drugs			19
Laboratory-confirmed cases		MDR/RR-TB: 49, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 49, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	82%	1 646
Previously treated cases, excluding relapse, registered in 2015	49%	98
HIV-positive TB cases registered in 2015	66%	209
MDR/RR-TB cases started on second-line treatment in 2014	50%	20
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2017

National TB budget (US\$ millions)	2.3
Funding source: 31% domestic, 27% international, 43% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

